HEALTH MANAGEMENT ASSOCIATES

The Intersection of HIV and Substance Use:

Enhancing the Care Continuum with Evidence-Based Practices

Training Series: Session 3
March 15, 2023

DEPARTMENT OF HUMAN SERVICES

Utilizing Zoom

- **Ensure your audio is linked to your Zoom participant ID.**
  - If you joined the audio by computer microphone and speaker, then you're all set.
  - If you joined the audio with a phone and did not enter your unique participant ID then enter **# <your participant ID> #** on your phone now. *Note: Your unique participant ID can be found by clicking on the lower left corner of your Zoom screen where it says 'Join Audio' and your Participant ID will appear.*

- **Ensure you are on MUTE and your camera is ON.** On the bottom left corner of your screen, you will see a red line through the microphone.



ON MUTE



Microphone ON



Camera OFF



Camera ON

- **Your participation throughout today via chat is appreciated!**

  Locate the chat box. On the bottom middle of your screen, click on the chat icon. This will open the "Zoom Group Chat" pane on the right side of your screen. You will see messages throughout the webinar on there. When prompted by the presenters, type in your answers or questions there.





Housekeeping

- Today is **Session 3**
- This series is eligible for both **CEUs** and **CMEs**
  - *These activities have been approved for CEUs by the Minnesota Board of Behavioral Health and Therapy for 3 hours of credit for LADCs and LPC/LPCCs (total of 12 hours if all four sessions are fully attended)*
  - *These activities have been approved for CMEs by the American Academy of Family Physicians for 3 hours of credit (total of 12 hours if all four sessions are fully attended)*
- **Please complete the evaluation for the webinar that will be sent out via email after each session.**
- **You will be receiving a PDF of today's presentation.**

- Follow-up questions?

  Contact Ryan Maganini: rmaganini@healthmanagement.com

Acknowledgments

We would also like to thank our **community partners** for their support in developing this curriculum.

Indigenous Peoples Task Force

Land Acknowledgment

Every community owes its existence and vitality to generations from around the world who contributed their hopes, dreams, and energy to making the history that led to this moment. Some were brought here against their will, some were drawn to leave their distant homes in hope of a better life, and some have lived on this land for more generations than can be counted. Truth and acknowledgment are critical to building mutual respect and connection across all barriers of heritage and difference.

We begin this effort to acknowledge what has been buried by honoring the truth. **We are standing on the ancestral lands of the Dakota people**. **We want to acknowledge the Dakota, the Ojibwe (oh-jib-way), the Ho Chunk, and the other nations of people who also called this place home.** We pay respects to their elders past and present.

Please take a moment to consider the treaties made by the Tribal nations that entitle non-Native people to live and work on traditional Native lands. Consider the many legacies of violence, displacement, migration, and settlement that bring us together here today. Please join us in uncovering such truths at any and all public events.*

*This is the acknowledgment given in the USDAC Honor Native Land Guide – edited to reflect this space by Shannon Geshick, MTAG, Executive Director Minnesota Indian Affairs Council

Today's Presenters

Linda Follenweider, MS, APRN
(she/her/hers)
Managing Director
Health Management Associates

Charles Robbins, MBA
(he/him/his)
Principal
Health Management Associates

Shannon Robinson, MD
(she/her/hers)
Principal
Health Management Associates

Disclosures

Faculty	Nature of Commercial Interest
Linda Follenweider, MS, APRN	Ms. Follenweider discloses that she is an employee of Health Management Associates, a national research and consulting firm providing technical assistance to a diverse group of health care clients.
Charles Robbins, MBA	Mr. Robbins discloses that she is an employee of Health Management Associates, a national research and consulting firm providing technical assistance to a diverse group of health care clients.
Shannon Robinson, MD	Dr. Robinson discloses that she is an employee of Health Management Associates, a national research and consulting firm providing technical assistance to a diverse group of health care clients.
Jeanene Smith, MD	Dr. Smith discloses that she is an employee of Health Management Associates, a national research and consulting firm providing technical assistance to a diverse group of health care clients.

Agenda for Webinar Series

Session	Topics
#1 **WEDNESDAY, MAR 1** 12:00 pm to 3:00 pm	❑ Understanding HIV ❑ HIV Testing and Treatment ❑ The Science of Addiction ❑ Screening, and Assessment
#2 **WEDNESDAY, MAR 8** 12:00 pm to 3:00 pm	❑ Ethical and Legal Issues ❑ Funding and Policy Considerations ❑ HIV Risk Reduction ❑ SUD Harm Reduction ❑ HIV and Stigma ❑ Motivational Interviewing
#3 **WEDNESDAY, MAR 15** 12:00 pm to 3:00 pm	❑ **Working with Justice Involved Persons** ❑ **Substance Use Disorder Treatment with Medications** ❑ **Mental Health Treatment and Counseling** ❑ **Stimulant Use** ❑ **Chem Sex**
#4 **WEDNESDAY, MAR 22** 12:00 pm to 3:00 pm	❑ Cultural, Racial and Sexual Identities ❑ HIV Positivity, Pregnancy, and SUD ❑ Accessing, Obtaining, and Integrating Services for Individuals with HIV and SUD in Minnesota

Time for a Poll

Please indicate the sector(s) in which you currently serve:

A. Community based organizations (Social Services, HIV, LGBT, etc.)
B. Corrections (includes Probation, Jail, Prison)
C. County Behavioral Health, Public Health, Human Services
D. Non-county behavioral health
E. Federally Qualified Health Center (FQHC)
F. Narcotic Treatment Program/Opioid Treatment Program
G. Outpatient Treatment Program
H. Residential Treatment Program
I. Aftercare services (e.g., sober living, other recovery housing, recovery community centers, etc.)
J. Harm Reduction Services/SSPs
K. Other (please specify in the chat)

Time for a Poll

Please indicate your primary role or discipline:

A. Physicians, Physician Assistant, Nurse Practitioners, Nurses (RN, LVN)
B. Social Workers
C. Addiction Counselors (LADCs)
D. Peer Recovery Support Positions
E. Substance Use Navigators (SUNs)
F. Administrators, Program Managers
G. Psychologists, LMFTs
H. Criminal Justice Professionals
I. Community Members
J. Other (please specify in the chat)

Glossary of Terms (revisited)

- **Sexual orientation –** a person's identity in relation to the gender or genders to which they are sexually attracted (straight, gay, lesbian, asexual, bisexual, pansexual)

- **Gender identity and/or expression** - internal perception of one's gender; how one identifies or expresses oneself.
  - **Cisgender** – a term used to describe a person whose gender identity aligns with those typically associated with the sex assigned to them at birth
  - **Transgender** – refers to an individual whose current gender identity and/or expression differs from the sex they were assigned at birth (may have transitioned or be transitioning in how they are living)
  - **Gender Expansive -** refers to an individual who expresses identity along the gender spectrum (genderqueer, gender nonconforming, nonbinary, agender, two spirit)
- **Sexual Minority** – refers to a group whose sexual identity orientation or practices differ from the majority of and are marginalized by the surrounding society.

SOURCE: Centers for Educational Justice and Community Engagement, UC Berkeley

Glossary of Terms (revisited)

- **Race** - is usually associated with inherited physical, social and biological characteristics. In this context that means race is associated with biology. Institutionalized in a way that has profound consequences (**White, African American, American Indian Alaskan Native, Native Hawaiian or Pacific Islander**)"
- **Ethnicity** - a term used to categorize a group of people with whom you share learned characteristics and identify according to common racial, national tribal, religious, linguistic, or cultural origin or background. (**Hispanic, Non-Hispanic Black, Non-Hispanic Black**, etc.)

SOURCE: US Office of Management and Budget: Federal Register Vol. 62(210): 58782

Common Acronyms (revisited)

ART – Antiretroviral therapy

AUD – Alcohol use disorder

IDU – Injection or intravenous drug use

MSM – Men who have sex with men

OUD – Opioid use disorder

PEH – Person(s) experiencing homelessness

PEP – Post-exposure prophylaxis

PrEP – Pre-exposure prophylaxis

PLWH – Person(s) living with HIV

PWID – Person(s) who injects drugs

SUD – Substance use disorder

Working with Justice-Involved Individuals

Learning Objectives:
Working with Justice-Involved Individuals

I

Describe the importance of substance use disorder treatment with medications in criminal justice settings

II

List 3 actions to take to ensure continuity of care for clients upon release from justice settings

III

Compare and contrast FDA approved medications for Alcohol Use Disorder (AUD), Opioid Use Disorder (OUD), and opioid reversal

Incarceration in MN by Facility



https://www.prisonpolicy.org/profiles/MN.html

Incarceration Rates in MN by Race

https://www.prisonpolicy.org/profiles/MN.html

MINNESOTA DEPARTMENT OF CORRECTIONS ADULT PRISON POPULATION SUMMARY (AS OF 07/01/2022)

Race/Ethnicity	Count	Percentage (%)
White	4,010	51.2%
Black	2,782	36.7%
American Indian	725	9.3%
Asian	205	2.6%
Unknown/Other	21	0.3%
Total	7,833	100%
Note: 425 (5.4%) of the above are of Hispanic ethnicity.		

Average age: 39.2
Average ADP 2022: 7,527
Males: 7.332 (93.6%)
Females: 501 (6.4%)

https://mn.gov/doc/assets/Adult%20Prison%20Population%20Summary%207-1-2022_tcm1089-534656.pdf

MINNESOTA DEPARTMENT OF CORRECTIONS ADULT PRISON POPULATION SUMMARY (AS OF 07/01/2022)

Top Six Offenses	Count	Percentage (%)
Criminal Sexual Conduct	1,512	19.3%
Homicide	1,511	19.3%
Drugs	1,203	15.4%
Assault	690	8.8%
Weapons	668	8.5%
Assault - Domestic	388	5.0%
Note: Percentages are based on the total population of 7,833.		

Releases (FY2022)	Count	Percentage (%)
Supervised Release/Parole	3,570	77.0%
Community Programs	683	14.7%
Discharge	281	6.1%
Work Release – COVID-19	55	1.2%
Other	43	0.9%
Cond Med Rel/Supv Release – COVID-19	7	0.2%
Total	4,639	100.0%

https://mn.gov/doc/assets/Adult%20Prison%20Population%20Summary%207-1-2022_tcm1089-534656.pdf

12 Month-ending Provisional Number of Drug Overdose Deaths

Based on data available for analysis on: 8/1/2021

Figure 1a. 12 Month-ending Provisional Counts of Drug Overdose Deaths: United States



Select Jurisdiction: United States

Predicted Value

Reported Value

Figure 1b. Percent Change in Reported 12 Month-ending Count of Drug Overdose Deaths, by Jurisdiction: January 2020 to January 2021



Select predicted or reported number of deaths

Predicted

Reported

Percent Change for United States

30.5

Legend for Percent Change in Drug Overdose Deaths Between 12-Month Ending Periods

-16.2 64.7

NOTES: *Reported* provisional counts for 12-month ending periods are the number of deaths received and processed for the 12-month period ending in the month indicated. Drug overdose deaths are often initially reported with no cause of death (pending investigation), because they require lengthy investigation, including toxicology testing. Reported provisional counts may not include all deaths that occurred during a given time period. Therefore, they should not be considered comparable with final data and are subject to change. *Predicted* provisional counts represent estimates of the number of deaths adjusted for incomplete reporting (see **Technical notes**).
Deaths are classified by the reporting jurisdiction in which the death occurred. Percent change refers to the relative difference between the reported or predicted provisional numbers of deaths due to drug overdose occurring in the 12-month period ending in the month indicated compared with the 12-month period ending in the same month of the previous year. Drug overdose deaths are identified using ICD–10 underlying cause-of-death codes: X40–X44, X60–X64, X85, and Y10–Y14.

+ableau

Unexpected response from 'GetSessionInfo' command when fetching online analytics server info.

https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm

Worsening Problem



https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm

HIV in Prison

An estimated 11,940 persons in the custody of state and federal correctional authorities were known to be living with HIV, a decline of nearly 16% from yearend 2019 (14,180).

FIGURE 1

Persons living with HIV and rate of HIV per 100,000 persons in the custody of state and federal correctional authorities, yearend 1991–2020



Note: Between one and four jurisdictions did not report the number of persons living with HIV in each year of the 30-year period from 1991 to 2020. Data were imputed for those jurisdictions not reporting data using various methods; therefore, numbers presented are estimates. See *Methodology*. See appendix table 1 for estimates.

Source: Bureau of Justice Statistics, National Prisoner Statistics, 1991–2020.

HIV in Prisons, 2020 – Statistical Tables (ojp.gov)

Burden of SUD and HIV in Carceral Settings

- It is estimated that 11% of 18-25 year olds, and 6% of those over 25 years old have a substance use disorder. It is estimated that 63% of people in jail and 58% in prison have a substance use disorder.*
- People with these disorders have challenges in getting appropriate treatment and often incarceration exacerbates their symptoms. This can lead to individuals staying incarcerated longer than those without behavioral health concerns.*
- Many jails and prisons are moving away from forced withdrawal which has been the historic approach to SUD in carceral settings.*
- Starting substance use disorder treatment with medications while incarcerated works better than post release.**
- The most recent Bureau of Justice Statistics HIV in Prisons report indicates HIV prevalence is 1.3 percent among state and federal prisoners; more than three times that of the general population. One study found one in five people with HIV are incarcerated in a jail or prison each year. ***

* https://www.samhsa.gov/criminal-juvenile-justice/about
**Rich J, et al. Methadone continuation versus force withdrawal on incarceration in a combined US prison and jail: a randomized open label trial. Lancet. 2015; 386: 350-359.
**Kinlock, TW et al. A randomized controlled trial of methadone maintenance for prisoners: results at twelve-months post release. J Substance Abuse Treatment 2009; 37(3): 277-85.
***Bureau of Justice Statistics, *Census of Jails*, 2019; and *Annual Survey of Jails*, 2020

Decrease in Jail Population does not Equal Decrease in Burden of Disease for Carceral Setting



THE PATIENT EXPERIENCE

*Bond Court

JAIL

Insurance Screening

INTAKE PROCESS
Everyone is screened on entry into jail for medical and mental health issues

HOUSED

Health Care Services Provided by Cermak at the Cook County Jail

- NURSING HEALTH SERVICE/TASKS
- PRIMARY CARE
- ONSITE SPECIALTY CARE
- CHRONIC CARE
- PHARMACY
- DENTAL CARE
- DIAGNOSTICS
- MENTAL HEALTH
- URGENT CARE
- COORDINATION OF OFFSITE SPECIALTY CARE
- MAT
- SPECIAL CARE
- DETOX
- NARCAN
- REPRODUCTIVE HEALTH CARE

DISCHARGE PLANNING & COMMUNITY LINKAGE FOR TRANSITION OF CARE

MAT | NARCAN | MH | AOT

Transition of Care: Definition

- **Transition of Care** – The movement of a patient from one setting of care (hospital, ambulatory primary care practice, ambulatory specialty care practice, long-term care, home health, rehabilitation facility) to another.

- Narcan on release
- Warm handoff to community provider
- Challenges in jails and beyond
  - No clear discharge date/time
  - Release not correlated to clinical condition
  - Housing options frequently suboptimal in supporting recovery
  - Overdose risk higher first two weeks post release
  - Variability in provision of substance use disorder treatment with medications

https://store.samhsa.gov/sites/default/files/d7/priv/sma16-4998.pdf

Community Opportunities to Minimize Incarceration

- Early identification of individuals with mental and substance use disorders at all points of contact with the justice system – pre-arrest, booking, adjudication, reentry.
- Use of screening and assessment to ensure linkage with evidence-based treatment, services and supports.
- Diversion of individuals from the justice system into home- and community-based treatment.
- Engaging law enforcement, first responders, and crisis management teams, justice court personnel, and community treatment providers in diversion strategies that meet both clinical and public safety needs.

https://store.samhsa.gov/sites/default/files/d7/priv/sma16-4998.pdf

Community Opportunities to Minimize Incarceration (cont.)

- Provision of training and technical assistance for law enforcement officers, juvenile and family court judges, probation officers, and other judicial decision-makers on behavioral health issues; and conversely, training for behavioral health treatment providers on criminogenic risk and the criminal and juvenile justice system.
- Provision of an array of services and supports to enable successful reentry into the community for those transitioning from incarceration or detention including housing.
- Assurance of equitable opportunities for diversion and linkage to community services and supports for all populations in order to decrease disproportionate minority contact with the justice system.
- Promotion of cross-sector collaboration to better serve these populations dually involved with the behavioral health and criminal justice systems.

https://store.samhsa.gov/sites/default/files/d7/priv/sma16-4998.pdf

Time for a Poll

Statement: My organization has an active working process to identify and provide a soft landing into the community for patients with complex care management needs related to addiction and HIV upon release from carceral settings.

A. Yes
B. No
C. Not Sure

Substance Use Disorder Treatment with Medications

What is Substance Use Disorder Treatment with Medications?

- The use of FDA-approved prescription medications, usually in combination with counseling and behavioral therapies, to provide a whole-person approach to the treatment of substance use disorders (SUD).

- When discussing medication for opioid use disorder this is frequently referred to as Substance Use Disorder Treatment with Medications is or Medications for Opioid Use Disorder (MOUD).

- MOUD has proven clinically effective to alleviate symptoms of withdrawal, reduce cravings, and block the brain's ability to experience the effect of opioids. MOUD maintenance has been proven to cut overdose rates in half and decrease rates of HIV and hepatitis C transmission.

- Research shows that a combination of MOUD and behavioral therapies is a successful method to treat OUD.

Which Substance Use Disorders are Treated with Medications?



Why is MOUD Important?

Treat Withdrawal	Address Dopamine Depletion	Treat OUD/Achieve Results

• Muscle pain, dilated pupils, nausea, diarrhea, abdominal cramping, piloerection
• Lasts 3-14 days
• Methadone or buprenorphine are recommended over abrupt cessation due to risk of return to use, overdose (OD) & death
	• Reward/motivation pathway abnormalities persists for months after people stop using
	• Treated with methadone or buprenorphine
		• Abstinence based treatment results in 85% using opioids within 1 year
		• MOUD decreases
		  • Use
		  • Craving
		  • Complications from IVDU
		  • Criminal behavior
		• MOUD increases retention in treatment

Sources: ASAM, (2020) National Practice Guidelines for the Treatment of OUD, Mattick, RP & Hall W (1996) Lancet 347: 8994, 97-100. Mattick, RP et al. (2008) Cochrane Systematic Review. Mattick, RP, et al. (2009) Cochrane Systematic Review. Lobmaier, P et al. (2008) Cochrane Systematic Review. Krupitsky et al. (2011) Lancet 377, 1506-13. Kakko et al. (2003) Lancet 361(9358),662-8. Rich, JD, et al. (2015) Lancet

FDA Approved Medication for OUD

Agonist Treatment (turns on the receptor):

- Methadone- approved for cough in 1940s, for OUD 1972
- Buprenorphine (Suboxone™ & Subutex™)- approved in 1981 for pain; oral approved for OUD 2002, patch, implants & injection later

Antagonist Treatment (blocks receptor from turning on):

- Naltrexone (Revia™)- oral approved 1984; injectable (Vivitrol™)2006 for AUD, 2010 for OUD
- Naloxone- approved 1961, autoinjector 2014, nasal spray (Narcan™) 2015

How do these medications work?



Agonist Treatment

Antagonist Treatment

Full, Partial, or No Effect

- Buprenorphine, Naloxone, and Naltrexone can all cause precipitated withdrawal.



Methadone: What and for Whom?

- Mu opioid receptor agonist
  - No “ceiling effect”
- Reaching a therapeutic dose takes time
  - <60 mg/d is not therapeutic
  - Typical dose 60-120 mg/d
  - Increased frequency and daily dose required during pregnancy
- Several significant drug-drug interactions
- Illegal to write prescription for methadone to treat OUD unless:
  - Narcotic Treatment Program (NTP)
  - Covering a gap of no more than 3 days
  - Patient is hospitalized

Patients with greater than a year of an OUD*

Patients with a more severe OUD, such as injecting opioids

Patients who have not reached tx goals with other MOUD

Patients who would benefit from the closest follow up

* Legislatively addressed in Omnibus bill; effective date pending

Methadone: General Federal Regulations



* OUD ≥1 y requirement for methadone removed by Omnibus Bill 12.29.22, 18 months for HHS to implement; Proposed Rule https://public-inspection.federalregister.gov/2022-27193.pdf

Methadone: Efficacy Data

- Methadone resulted in 33% fewer opioid positive toxicology tests compared to those receiving no medication*
  - Everyone receiving psychosocial treatment
- 4.4x more likely to stay in treatment *
- Reduced crime *
- Reduced infectious disease*
- Reduced death**

Source:
* Mattick 2009 Cochrane Review
** Wakeman 2020 JAMA Open Network

Buprenorphine: What and for Whom?

- Partial mu opioid agonist with ceiling effect
  - Available alone or in combination w/naloxone
  - Doses >32 mg don't cause greater effect
  - Different formulations (sub-lingual [SL] buccal pill/film, injectable)
- Greater binding affinity than full agonists
  - Start buprenorphine when client in moderate withdrawal (to avoid causing precipitated withdrawal)
  - Other opioids are not as effective when buprenorphine is present
  - Typical dose is 16-24 mg/d
  - Increased frequency and daily dose required during pregnancy
- Fewer drug-drug interactions than methadone

Opioid use disorder or withdrawal

Patient wants agonist treatment

Buprenorphine: General Regulations

DEA X-Waiver updates
https://www.deadiversion.usdoj.gov/pubs/docs/index.html
X waiver no longer required
Use standard DEA number for buprenorphine prescriptions
No cap on number of people treated with buprenorphine

Buprenorphine: Efficacy Data

- Rate of return to opioid use for placebo was 100% vs 25% for buprenorphine
- If taking ≥16mg buprenorphine you are 1.82 times more likely to stay in treatment than if on placebo
- Decreased death*

Source:
NIDA Medications to Treat Opioid Use Disorder Research Report Updated December 2021
Mattick 2014 Cochrane Review
* Wakeman 2020 JAMA Open Network

Naloxone: OD Reversal Agent as Harm Reduction

- Mu opioid antagonist
- Shorter half-life & more rapid onset of action than naltrexone
- High affinity, competitive binding & displaces agonists
- Intranasal or intramuscular by bystander
- May require more than one dose
- Opioids have longer half-life than naloxone
- Saves lives; no evidence for increasing drug use
- Good Samaritan law in MN
- <1% of those in need have access



Naloxone Resources

- https://www.health.state.mn.us/communities/opioids/opioid-dashboard/resources.html#naloxone
- University of Minnesota Naloxone Resources https://www.pharmacy.umn.edu/degrees-and-programs/continuing-pharmacy-education/continuing-education-courses/naloxone
- Naloxone overdose training and kits free of charge. The following community-based organizations provide Naloxone overdose training and kits free of charge:
- Steve Rummler HOPE Network—Call 952-943-3937 or sign up for training from the Steve Rummler HOPE Network.
- Rural AIDS Action Network (RAAN)—Call 320-257-3036.
- Red Door Clinic—Call 612-543-5555.
- Indigenous Peoples Task Force—Call 612-870-1723.
- Lutheran Social Services—Call 800-582-5260

Time for a Poll

Do you know if your organization is currently prescribing (or providing) or doing any training on naloxone?

a) Yes

b) No

c) I don't know

Naltrexone: What and for Whom?

- Mu opioid antagonist with high, competitive binding affinity
- Does not treat withdrawal or underlying dopamine depletion
- Must be opioid free x 7 days before starting
- More widespread acceptance in criminal justice and "abstinence-only" communities
- Evidence of decreased mortality is limited

Patients with a high degree of motivation (dopamine)

Patients with a history of OUD and Alcohol Use Disorder (AUD)

Patients who had poor results with methadone or buprenorphine

Can be useful for occasional use or after discontinuation of methadone or buprenorphine

Source: Larochelle, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality. A cohort study. Annals of Internal Medicine. 169:3 (2018) 137-45.

Naltrexone: General Regulations

No Federal regulations inhibit the use

Not all BH clinics have RN to give injections

Multiple formulations:

- Pills at 25mg and 50 mg (50-100 mg for AUD)
- Long acting injectable 380mg (28-30 days)

Naltrexone: Efficacy Data

- XR Naltrexone 90% opioid abstinent toxicology tests vs. 35% placebo*
  - Decreased incarceration**
  - Does not decrease death***
- XR Naltrexone vs usual care in HIV clinic****
  - Fewer days of opioid use for those on XR Naltrexone

Source:
*Krupitsky 2011 Lancet
**Minozzi 2011 Cochrane Review
***Wakeman 2020 JAMA Open Network
**** Korthuis 2022

How Long to Treat OUD?

It takes over a year for brain healing to occur

- Studies of all FDA approved meds for OUD indicate a risk of return to opioid use upon discontinuation of meds
- **Year(s) post sobriety,** if making appropriate changes to decrease likelihood of future substance use, stable in recovery and life and wants to discontinue
  - Social Support that supports recovery
    - Active in 12 step meetings or
    - Active in Self-Management and Recovery Training (SMART) meetings or
    - Active in church
    - Not living with people who are using
  - Able to handle interpersonal conflicts without relapsing…
  - Avoid tapering during big life transitions such as leaving incarceration, pregnancy or delivery, moving across the country, changing jobs

To taper or not to taper?

Evidence is clear that long-term or indefinite treatment with medications for OUDs is often required for effective and sustained outcomes[1]

In practice, successful tapers from methadone or buprenorphine typically occur in only about 15 percent of cases[2,3]

According to the U.S. Surgeon General, successful tapers typically occur, if at all, when individuals have been treated with Medicated Assisted Treatment (MAT) for at least 3 years[4]

1. National Academies of Sciences, Engineering, and Medicine. (2019). *Medications for opioid use disorder save lives.* Washington, DC: The National Academies Press.
2. Nosyk, B., Sun, H., Evans, E., Marsh, D. C., Anglin, M. D., Hser, Y. I. et al. (2012). Defining dosing pattern characteristics of successful tapers following methadone maintenance treatment: Results from a population-based retrospective cohort study. *Addiction,* 107, 1621-1629.
3. Substance Abuse and Mental Health Services Administration. (2018). *Medications for opioid use disorder: Treatment improvement protocol (TIP 63) for healthcare and addiction professionals, policy makers, patients and families.* (Rep. No. HHS Publication No. SMA 18-5063). Bethesda, MD: Author.
4. Substance Abuse and Mental Health Services Administration and Office of the Surgeon General. (2018). *Facing addiction in America: The Surgeon General's spotlight on opioids.* Washington, DC: US Department of Health and Human Services.

References: OUD Medication

- The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update. (2020) J Addict Med14(2S Suppl 1):1-91. doi: 10.1097/ADM.0000000000000633. Erratum in: J Addict Med. 2020 May/Jun;14(3):267. PMID: 32511106.
- https://www.deadiversion.usdoj.gov/pubs/docs/index.html Eliminating the X Waiver
- www.druginserts.com
- Healthresearchfunding.org(2019) https://healthresearchfunding.org/24-opiate-addiction-recovery-statistics/ 24 Shocking Opiate Addiction Recovery Statistics
- Korthuis PT, et. al. HIV clinic-based extended-release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non-blinded, randomized non-inferiority trial. Addiction. 2022 Jul;117(7):1961-1971. doi: 10.1111/add.15836. Epub 2022 Mar 2. PMID: 35129242; PMCID: PMC9314106.
- Krupitsky, et. al. Injectable extended-release naltrexone for opioid dependence: a double-blind placebo controlled, multicenter randomized trial. 2011; Lancet 377: 1506-13.
- Kakko et al. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet (2003) 361(9358):662-8.
- Larochelle, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality. A cohort study. Annals of Internal Medicine. 169:3 (2018) 137-45.
- Mattick, RP, et al. (2009) Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Systematic Review.
- Mattick, RP, et al. (2014) Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Systematic Review.
- Metzger DS et al., “Human Immunodeficiency Virus Seroconversion Among Intravenous Drug Users In- and Out-of-Treatment: An 18-Month Prospective Follow-Up,” Journal of Acquired Immune Deficiency Syndromes 6, no. 9 (1993): 1049–56, http://www.ncbi.nlm.nih.gov/pubmed/8340896.

References: OUD Medication

- Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A. Oral naltrexone maintenance treatment for opioid dependence. *Cochrane Database Syst Rev*. 2011;2011(4):CD001333. Published 2011 Apr 13. doi:10.1002/14651858.CD001333.pub4
- NIDA Medications to Treat Opioid Use Disorder Research Report Updated December 2021.
- Principals of Drug Addiction Treatment: A Research Based Guide." National Institute on Drug Abuse. Ed. NIDA International Program.
- https://public-inspection.federalregister.gov/2022-27193.pdf Proposed Rules MOUD
- Rich, JD, et al. Continuation versus forced withdrawal on incarceration in a combined US prison and jail: a randomised, open-label trial. Lancet (2015) 386 (9991): 350-359.
- Substance Abuse Mental Health Services Agency. Medications for Opioids Use Disorder: For Healthcare and Addiction Professionals, Policymakers, Patients and Families. Rockville MD SAMHSA Treatment Improvement Protocol (TIP) Series, No. 63 (2021).
- Schwartz RP, et al. Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009. Am J Public Health. 2013 May;103(5):917-22. doi: 10.2105/AJPH.2012.301049. Epub 2013 Mar 14. PMID: 23488511; PMCID: PMC3670653
- Treatment Research Institute (TRI), Ed. "Cost Utilization Outcomes of Opioid Dependence Treatment" American Journal of Managed Care 2011.
- Tsui, JI et al., "Association of Opioid Agonist Therapy With Lower Incidence of Hepatitis C Virus Infection in Young Adult Injection Drug Users," JAMA Internal Medicine 174, no. 12 (2014): 1974–81, http://archinte.jamanetwork.com/article.aspx?articleid=1918926
- Wakeman, SE. et. al. (2020) Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder. JAMA Open Network. 3 (2).

Why Medications for Alcohol Use Disorder is Important?

- Increased retention in treatment
- Decreased drinking
- Decreased cravings
- Decreased healthcare costs

- Disulfiram
- Naltrexone (oral and intramuscular)
- Acamprosate

Disulfiram: Mechanism of Action



Disulfiram for Alcohol Use Disorder (AUD)

- Approved decades ago; most recent data does NOT show overwhelming efficacy*
- Once per day dosing
- Inhibits multiple P450 and other liver enzymes
- Drug Interactions: benzodiazepines, phenytoin, pimozide, tricyclic antidepressants (TCAs), warfarin, sulfonylureas, metronidazole, amoxicillin, isoniazid
- Contraindications/precautions: **alcohol use,** hypersensitivity to rubber, severe coronary artery disease (CAD), cirrhosis, severe renal impairment, psychosis, depression, diabetes mellitus (DM), epilepsy
- Extensively metabolized
- Extensive list of side effects

Source: * Garbutt JC, West SL, Carey TS, et al. Pharmacological treatment of alcohol dependence. J Am Med Assoc. 1999; 281(14):1318-1325.

Naltrexone for AUD

- Few side effects
- Drug Interactions: opioids
  - No P450 interactions
- Contraindications: severe acute hepatitis
- Well studied in mild and moderate cirrhosis
- Safe in mild renal disease

Naltrexone Efficacy: Grade A

	Oral	Intramuscular
Reduced drinking days	Yes	Yes
Reduced heavy drinking days	Yes	Yes
Decreased opioid use	Yes	Yes
Decreased cravings	Yes	
Increased time to first drink	Yes	Yes
Treatment retention	Higher	Highest
Discontinuation of medication		Lower than oral
Decreased ED visits		Lower
Decreased hospitalizations		Lower
Decreased pharmacy cost		Lower
Decreased nonpharmacy costs		Lower

Acamprosate: Mechanism

Glutamate Cell



Glutamate

Acamprosate

N-methyl-D-aspartic acid receptor (NMDA)

Gamma Amino Butyric Acid (GABA) cell

In someone with an active alcohol use disorder acamprosate decreases glutamate release and decreases GABA transmission

Acamprosate for AUD

- Effective: Grade A recommendation
- Three times per day dosing
- Drug Interactions: none
- Contraindications: severe renal impairment
- 333mg three times a day (TID) moderate renal impairment (creatinine clearance 30-50ml/m)
- Few side effects
- No metabolism

Time for a Poll

Question: Do you know anyone on medication for AUD?

A. Yes
B. No

References: AUD Medication

- Chick, J., Lehert, P., & Landron, F. (2003). Does Acamprosate Improve Reduction of Drinking As Well As Aiding Abstinence? Journal of Psychopharmacology, 17(4), 397–402. doi:10.1177/0269881103174017
- Garbutt, J. C., West, S. L., Carey, T. S., Lohr, K. N., & Crews, F. T. (1999). Pharmacological Treatment of Alcohol Dependence. JAMA, 281(14), 1318. doi:10.1001/jama.281.14.1318.
- Kahan, M., Wilson, L., & Becker, L. (1995). Effectiveness of physician-based interventions with problem drinkers: a review. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 152(6), 851–859.
- Mann, K., Lehert, P., & Morgan, M. Y. (2004). The Efficacy of Acamprosate in the Maintenance of Abstinence in Alcohol-Dependent Individuals: Results of a Meta-Analysis. Alcoholism: Clinical & Experimental Research, 28(1), 51–63. doi:10.1097/01.alc.0000108656.81563.05
- Solberg, L. I., Maciosek, M. V., & Edwards, N. M. (2008). Primary Care Intervention to Reduce Alcohol Misuse. American Journal of Preventive Medicine, 34(2), 143–152.e3. doi:10.1016/j.amepre.2007.09.035
- Substance Abuse and Mental Health Services Administration and National Institute on Alcohol Abuse and Alcoholism, Medication for the Treatment of Alcohol Use Disorder: A Brief Guide. HHS Publication No. (SMA) 15-4907. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2015.
- Srisurapanont, M., & Jarusuraisin, N. (2005). Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials. The International Journal of Neuropsychopharmacology, 8(2), 267–280. doi:10.1017/s1461145704004997
- Tidey et al. (2008) Moderators of naltrexone's effect on drinking, urge and alcohol effects in non-treatment-seeking heavy drinkers in natural environment. Alcohol Clin Exp Res; 32 (1): 58-66.
- Wong, J., Saver, B., Scanlan, J. M., Gianutsos, L. P., Bhakta, Y., Walsh, J., ... & Rudolf, V. (2020). The ASAM clinical practice guideline on alcohol withdrawal management. Journal of Addiction Medicine, 14(3S), 1-72.

5-minute stretch break!

Counseling for Co-Occurring HIV & SUD

Learning Objectives:

Counseling for Co-Occurring HIV & SUD

I

Discuss coping with a HIV diagnosis and preparing patients for disclosure

II

Identify at least 3 considerations for mental health treatment of individuals with HIV and SUD

III

Distinguish acute and chronic risk of suicidality in individuals with HIV and SUD

Why is it Important to Address SUD in Persons with HIV?

Substance use accelerates the progression of HIV

- Increases viral load
- Increases likelihood of AIDs related morbidity (even when adherent to antiretroviral medications)
- Decreases medication adherence



Sources: Dash, 2015; Schaffer 2017; Strazza 2011; Dahal 2015; Andriote 2012;
NIDA 2021 https://www.drugabuse.gov/publications/research-reports/common-comorbidities-substance-use-disorders/

Why is it Important to Address SUD in Persons with HIV?

"Substances of abuse" weaken the blood brain barrier

- Allowing HIV to more easily enter the brain
- Allows infection and damage to nerves and supporting cells (glia)
- Triggers release of neurotoxins
- Can lead to dementia
  - 50% of people with HIV have neurocognitive disorders

Sources: Dash, 2015; Schaffer 2017; Strazza 2011; Dahal 2015; Andriote 2012;
NIDA 2021 https://www.drugabuse.gov/publications/research-reports/common-comorbidities-substance-use-disorders/

HIV Testing

- 19% of 15-44yo in the United States were tested for HIV in the past year
- Only one-third of SUD programs offer onsite HIV testing



Sources:
NIDA 2021 https://www.drugabuse.gov/publications/research-reports/common-comorbidities-substance-use-disorders
Substance Abuse and Mental Health Services Administration. (2021). Treating Substance Use Disorders Among People with HIV. Advisory.

HIV Testing Recommendations

- ✓SAMHSA recommends universal HIV testing for
  - Persons 15-65yo (and all pregnant persons)
  - Younger and older persons at increased risk, such as:
    - People who inject drugs
    - People who have condomless sex
    - People who participate in commercial sex work
- ✓US Preventative Task Force Rating A
  - Requires Medicare and Medicaid to pay for testing
  - Rapid tests are available- results within 30 minutes
  - Provide pre and post test counseling- reviewed in other talks

Sources:
NIDA 2021 https://www.drugabuse.gov/publications/research-reports/common-comorbidities-substance-use-disorders
Substance Abuse and Mental Health Services Administration. (2021). Treating Substance Use Disorders Among People with HIV. Advisory.

STTR Model of Care

- Testing persons who inject drugs every 6 months is cost effective
- **Recommendation:** Inpatient and outpatient mental health settings should offer routine opt out testing to improve case finding



Chart review compared to blood samples from 2 inpatient psychiatric units: 21% of patients with HIV positive blood samples did not have documentation of infection in medical record

Sources: NIDA 2021 https://www.drugabuse.gov/publications/research-reports/common-comorbidities-substance-use-disorders
Hutchinson AB, Farnham PG, Sansom SL, Yaylali E, Mermin JH. Cost-Effectiveness of Frequent HIV Testing of High-Risk Populations in the United States. *J Acquir Immune Defic Syndr 1999.* 2016;71(3):323-330. doi:10.1097/QAI.0000000000000838.
Galletly CL, Pinkerton SD, Petroll AE. CDC recommendations for opt-out testing and reactions to unanticipated HIV diagnoses. AIDS Patient Care STDS. 2008 Mar;22(3):189-93. doi: 10.1089/apc.2007.0104. PMID: 18290754; PMCID: PMC2728134.
Branson BM, Handsfield HH, Lampe MA, Janssen RS, Taylor AW, Lyss SB, Clark JE; Centers for Disease Control and Prevention (CDC). Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006 Sep 22;55(RR-14):1-17; quiz CE1-4. PMID: 16988643.
Rothbard AB, Blank MB, Staab JP, et al. Previously Undetected Metabolic Syndromes and Infectious Diseases Among Psychiatric Inpatients. *Psychiatric services.* 2009;60(4):534–537.

Epidemiology- HIV & Depression

- Up to 70% of people living with HIV have a history of trauma
- 54% of people living with HIV have post-traumatic stress disorder (PTSD)
- People living with HIV are twice as likely to develop depressive symptoms compared to those at risk but who are not living with HIV
- People living with HIV experience higher rates of depression than the general population
- Key feature of depression, as compared to adjustment disorder or side effects from medication, is loss of pleasure

Sources: Kessler, R.C. 2005, Andriote, JM. 2012, Gaynes, B.N. 2008, Blank M.B.2013

Epidemiology- HIV & Mental Illness



- Twenty-two percent (22%) of people with HIV have depression
  - Of those 78% **ALSO** have an anxiety disorder
  - Of those 61% **ALSO** have an SUD
- Six percent (6%) of people with HIV have schizophrenia, as compared to 1% of the general population
- Those with schizophrenia are **1.5x** as likely to contract HIV
- Those with affective disorders were **3.8x** as likely to contract HIV

Sources: Kessler, R.C. 2005, Andriote, JM. 2012, Gaynes, B.N. 2008, Blank M.B.2013

SUD, HIV and Mental Illness

- Only 35% of people in 10 outpatient HIV clinics reported talking to primary care provider (PCP) about alcohol use
- < 50% of providers in hospital-based HIV care programs conducted recommended screening and brief interventions for reducing alcohol
- Substance use may increase high-risk sexual practices



Sources: Staruss, S.M. 2009
Andriote, JM. 2012

Counseling: Coping with an HIV Diagnosis

- Coping with the diagnosis of HIV
  - is a form of grieving
  - is different from having a major depressive episode
  - may require treatment
    - support or psychotherapy
    - will not respond to antidepressants

Sources: Andriote, JM. 2012 http://wwwaidsmap.com/news/aug-2021/hardest-outcome-all-hiv-and suicide

Counseling Recommendations

1. Don't try to solve or fix things, but….
   - Housing is important
   - Social support is important
   - Medical care is important
   - These things helps establish a sense of control over one's life
2. Don't minimize someone's feelings
3. Don't tell people to pull themselves together
4. Listen… for risks and for talk of the <u>future</u>

Sources: Andriote, JM. 2012 http://wwwaidsmap.com/news/aug-2021/hardest-outcome-all-hiv-and suicide

Considerations for Mental Health Treatment of Individuals with HIV and SUD

- Major Depression, among those living with HIV, responds to the same treatments:
  - Evidence-based psychotherapy
  - Evidence-based medications
    - *As with other conditions, keep drug-drug interactions in mind*
- Depression & bipolar disorder can make medication adherence challenging

ANTIDEPRESSANT TREATMENT OF DEPRESSION RESULTS IN LOWER HEALTHCARE COSTS

- Persons with bipolar disorder and HIV are more likely to have unprotected intercourse with HIV negative partners
- The risk of suicide is higher for those with HIV (at all stages) as compared to the general population

Sources: Andriote, JM. 2012 & Blank MB 2013

SUD Treatment For Those Living with HIV

- Cognitive Behavioral Therapy (CBT) & Motivational Interviewing (MI)
  - Reduce drug use
  - Reduce high risk sexual behaviors
  - Reduce viral load
  - Improve adherence to antiretrovirals
- Medication for opioid use disorder
  - Methadone and buprenorphine are associated with a 54% reduction in risk of HIV infection in persons who inject drugs

SUD Treatment is HIV Prevention!

Source: NIDA 2021 https://www.drugabuse.gov/publications/research-reports/common-comorbidities-substance-use-disorders

Epidemiology- Suicidality & HIV

Suicide

- 3rd most common cause of death in 15-29yo women
- 4th most common cause of death in 15-29yo men
- No relationship to income
- A life-threatening illness is a one of the most strongly predictive factors for completed suicide
- Suicide rate in the first year after an HIV diagnosis is **5x** the rate in the general population. Suicide in the first year after an HIV diagnosis accounts for **40%** of all suicide in persons with HIV.

Suicide Attempt Rate

People living with HIV: 16%

General Population: 3%

Suicidal Ideation Rate

People living with HIV: 23%

General Population: 9%

Sources: http://wwwaidsmap.com/news/aug-2021/hardest-outcome-all-hiv-and suicide
https://www.health.state.mn.us/people/syringe/suicide.pdf

Time for a Poll

People who talk about suicide, do not complete suicide.

A. True
B. False

Risk Factors for Suicide

- ❑ Trauma
- ❑ Triggering event-stressor
- ❑ Ideation & past behavior
- ❑ Health-medical, mental and substance
- ❑ Purposeless, hopeless
- ❑ Poor sleep
- ❑ Mood, anxiety, anger, withdrawal
- ❑ Reckless, impulsive

Sources: https://www.health.state.mn.us/people/syringe/suicide.pdf

Assessment for Suicidality

- Which factors can be modified to reduce risk?
  - Opportunities for healing
  - Reduce harms
- Protective factors
  - Connectedness
  - Support
  - Skills- problem solving, coping, healing



Sources: https://www.health.state.mn.us/people/syringe/suicide.pdf

Assessment Recommendations

1. Be mindful that protective factors are unique to each person
2. Use the person's language
3. Ask open ended questions such as:
   - What are things that keep you safe?
   - When this occurred in the past what has stopped you?
   - Who are the people who lift your spirits?
   - What activities lift your spirits?
   - What would you like to develop within yourself in the future?
4. Try to identify protective factors that can be enhanced

Sources: https://www.health.state.mn.us/people/syringe/suicide.pdf

Integrated Primary HIV & Behavioral Health Care

Benefits of Integration

- Increases likelihood of follow through on referrals
- Improve physical health outcomes
- Increased savings in healthcare cost
- Reduce emergency room use

Ryan White HIV/ AIDS Treatment Extension Act 2009

- Aligns with HHS guidelines
- Mandates include:
    1. Universal depression and SUD screening
        - MH screening rates currently are between 80%-100%
        - SUD screening rates currently are much lower
    2. Establishment of follow up plan

References:

- Dash S, Balasubramaniam M, Villalta F, Dash C, Pandhare J. Impact of cocaine abuse on HIV pathogenesis. Front Microbiol. 2015 Oct 20;6:1111. doi: 10.3389/fmicb.2015.01111. PMID: 26539167
- Schaefer CP, Tome ME, Davis TP. The opioid epidemic: a central role for the blood brain barrier in opioid analgesia and abuse. Fluids Barriers CNS. 2017 Nov 29;14(1):32. doi: 10.1186/s12987-017-0080-3. PMID: 29183383
- Strazza M, Pirrone V, Wigdahl B, Nonnemacher MR. Breaking down the barrier: the effects of HIV-1 on the blood-brain barrier. Brain Res. 2011 Jul 5;1399:96-115. doi: 10.1016/j.brainres.2011.05.015. Epub 2011 May 14. PMID: 21641584
- Dahal S, Chitti SV, Nair MP, Saxena SK. Interactive effects of cocaine on HIV infection: implication in HIV-associated neurocognitive disorder and neuroAIDS. Front Microbiol. 2015 Sep 8;6:931. doi: 10.3389/fmicb.2015.00931. PMID: 26441868
- Andriote. HIV and Clinical Depression APA Fact Sheet 2012, Arlington VA
- NIDA 2021 https://www.drugabuse.gov/publications/research-reports/common-comorbidities-substance-use-disorders
- Substance Abuse and Mental Health Services Administration. (2021). Treating Substance Use Disorders Among People with HIV. Advisory.
- Blank MB, Himelhoch S, Walkup J, Eisenberg MM. Treatment considerations for HIV-infected individuals with severe mental illness. Curr HIV/AIDS Rep. 2013 Dec;10(4):371-9. doi: 10.1007/s11904-013-0179-3. PMID: 24158425
- Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005 Jun;62(6):593-602. doi: 10.1001/archpsyc.62.6.593. Erratum in: Arch Gen Psychiatry. 2005 Jul;62(7):768. PMID: 15939837.

References:

- Andriote, J. APA Fact Sheet HIV mental health treatment issues HIV and clinical depression 2012
- Gaynes BN, Pence BW, Eron JJ Jr, Miller WC. Prevalence and comorbidity of psychiatric diagnoses based on reference standard in an HIV+ patient population. Psychosom Med. 2008 May;70(4):505-11. doi: 10.1097/PSY.0b013e31816aa0cc. Epub 2008 Mar 31. PMID: 18378865
- Strauss SM, Rindskopf DM. Screening patients in busy hospital-based HIV care centers for hazardous and harmful drinking patterns: the identification of an optimal screening tool. J Int Assoc Physicians AIDS Care (Chic). 2009 Nov-Dec;8(6):347-53. doi: 10.1177/1545109709350509. Epub 2009 Oct 22. PMID: 19850861
- Substance Abuse and Mental Health Services Administration and Health Resources and Services Administration, The Case for Behavioral Health Screening in HIV Care Settings. HHS Publication No. SMA-16-4999. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2016.
- NIDA, 2021. https://www.drugabuse.gov/publications/research-reports/common-comorbidities-substance-use-disorders
- Hutchinson AB, Farnham PG, Sansom SL, Yaylali E, Mermin JH. Cost-Effectiveness of Frequent HIV Testing of High-Risk Populations in the United States. J Acquir Immune Defic Syndr 1999. 2016;71(3):323-330. doi:10.1097/QAI.0000000000000838.
- Galletly CL, Pinkerton SD, Petroll AE. CDC recommendations for opt-out testing and reactions to unanticipated HIV diagnoses. AIDS Patient Care STDS. 2008 Mar;22(3):189-93. doi: 10.1089/apc.2007.0104. PMID: 18290754; PMCID: PMC2728134.
- Branson BM, Handsfield HH, Lampe MA, Janssen RS, Taylor AW, Lyss SB, Clark JE; Centers for Disease Control and Prevention (CDC). Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006 Sep 22;55(RR-14):1-17; quiz CE1-4. PMID: 16988643.
- Rothbard AB, Blank MB, Staab JP, et al. Previously Undetected Metabolic Syndromes and Infectious Diseases Among Psychiatric Inpatients. Psychiatric services. 2009;60(4):534–537.

Stimulant Use

Learning Objectives:

Stimulant Use and Persons Who Engage In Chemsex

I

List at least 5 risks associated with methamphetamine usage

II

Define and identify at least 2 benefits of contingency management

III

Identify at least 3 risk behaviors of persons who engage in Chemsex

What are Stimulants?

- Cocaine
- "Psychostimulants with abuse potential"
  - Mahuang, ephedra & khat- plants
  - Pseudoephedrine, ephedrine & cathinone & cathine- chemical in above plants
  - "Bath salts" (synthetic man made cathinones)
  - Amphetamine (synthetic)
    - Methamphetamine (dextro & levo)
    - Amphetamine (dextro & levo)
    - MDMA/ecstasy = Molly = methylenedioxy-methamphetamine
    - Methylphenidate = Ritalin™
  - Methylxanthines (naturally occurring)
    - Caffeine (coffee)
    - Theophylline (tea)
    - Theobromine (chocolate)

Drug Seizures in Minnesota



Source: Minnesota Department of Public Safety, Violent Crime Enforcement Teams (VCET) Dashboard
https://dps.mn.gov/divisions/ojp/statistical-analysis-center/Pages/vcet-dashboards.aspx

Admissions to SUD Treatment: MN



Cocaine Use Nationally & Locally



Source: https://pdas.samhsa.gov/saes/state

Amphetamine Use Nationally & Locally



Source: https://pdas.samhsa.gov/saes/state

Stimulant Use Minnesota



Source: https://pdas.samhsa.gov/saes/state

Methamphetamine Emergency Visits & Hospital Utilization in the U.S.





Source: https://www.nihcm.org/categories/beyond-opioids-rapid-increase-in-drug-deaths-involving-stimulants

Stimulant Overdose Deaths
Continue to Rise Nationally and Locally

Based on data available for analysis on: February 5, 2023

*After opening the **drug class dropdown**, click the top of the dropdown menu again to make the checkboxes disappear.*

Select Jurisdiction: United States

Select specific drugs or drug classes: Select drug class

Figure 2. 12 Month-ending Provisional Number of Drug Overdose Deaths by Drug or Drug Class: United States



United States

Based on data available for analysis on: February 5, 2023

*After opening the **drug class dropdown**, click the top of the dropdown menu again to make the checkboxes disappear.*

Select Jurisdiction: Minnesota

Select specific drugs or drug classes: Select drug class

Figure 2. 12 Month-ending Provisional Number of Drug Overdose Deaths by Drug or Drug Class: Minnesota



Minnesota

Source: https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm#dashboard

Psychostimulant Overdoses with and without Opioids

Figure 6. National Overdose Deaths Involving Psychostimulants with Abuse Potential (Primarily Methamphetamine)*, by Opioid Involvement
Number Among All Ages, 1999-2020



*Among deaths with drug overdose as the underlying cause, the psychostimulants with abuse potential (primarily methamphetamine) category was determined by the T43.6 ICD-10 multiple cause-of-death code. Abbreviated to *psychostimulants* in the bar chart above.
Source: Centers for Disease Control and Prevention, National Center for Health Statistics. Multiple Cause of Death 1999-2020 on CDC WONDER Online Database, released 12/2021.

Cocaine Overdoses with and without Opioids

Figure 7. National Drug Overdose Deaths Involving Cocaine*, by Opioid Involvement, Number Among All Ages, 1999-2020



*Among deaths with drug overdose as the underlying cause, the cocaine category was determined by the T40.5 ICD-10 multiple cause-of-death code. Source: Centers for Disease Control and Prevention, National Center for Health Statistics. Multiple Cause of Death 1999-2020 on CDC WONDER Online Database, released 12/2021.

Source: https://www.drugabuse.gov/drug-topics/trends-statistics/overdose-death-rates

In the Chat box please answer this question:

Do you prefer:

Coffee

Tea

Chocolate

Soda

I refuse to pick just one

Image provided by Unsplash Photos

Medicinal Uses for Stimulants

- Cocaine- used as a vasoconstrictor & numbing agent
- "Psychostimulants with abuse potential"
  - Ephedra- made into pseudoephedrine and used for allergies and colds
  - Khat used for depression, obesity, fatigue in middle east
  - Amphetamines are used for obesity, narcolepsy & Attention Deficit Hyperactivity Disorder
  - Methylxanthines
    - Caffeine (coffee)
    - Theophylline (tea) used for asthma
    - Theobromine (chocolate)

<u>Amphetamine dosing:</u>
ADHD 2.5 mg/day to 70mg/ day
Narcolepsy 5 mg/day to 60 mg/day

<u>Methamphetamine dosing:</u>
ADHD approved but not commonly used
5 mg/day to 25 mg/ day

Illicit use of amphetamines/ methamphetamines up to 1 g / day

Some Consequences are due to Mode of Consumption

- Smoking
  - Burned lips
  - Throat problems
  - Lung problems- acute (50% of those who smoke cocaine) and chronic





- Injection (unsafe practices)
  - Skin & heart infections
  - Hepatitis or HIV

- Snorting
  - Sinus infections
  - Holes in nasal septum
  - Nosebleeds
  - Hoarseness

NOTE:
There is cross tolerance from one class of stimulants to another

Effects Dependent Upon Mode of Consumption

Drug Reaches Brain

- Smoking- seconds
- Injection- seconds
- Snorting- 15 minutes
- Oral-45 minutes

Half-Life

- Cocaine 1h
- Bath Salts 3 hours
- Amphetamine 7 hours
- Methamphetamines 12 hours

Time for a Poll

Have you had trouble retaining patients with stimulant use disorders in treatment?

a) Yes

b) No

Stimulants Effecta on Brain Chemistry

Cocaine:
Reuptake Blocker

INDIRECT agonist of

+ dopamine
+ norepinephrine
+ serotonin

BLOCKS

+ **monoamine reuptake**
+ **sodium channels**



Amphetamines:
Releaser

INDIRECT agonist of

+ dopamine
+ norepinephrine
+ serotonin

INHIBITS

+ **metabolism of monoamines**
+ **vesicular storage**

REVERSES reuptake

Photo Source: https://www.drugabuse.gov/news-events/nida-notes/2017/03/impacts-drugs-neurotransmission

Acute Effects of Stimulants

- Increased
  - Alertness/vigilance, concentration, mental acuity
  - Energy, locomotion
  - Sensory awareness & sexual desire
  - Self confidence, grandiosity, anxiety, irritability, paranoia
  - Heart rate & blood pressure, irregular heartbeat, vasoconstriction
  - Breathing rate, temperature, pupil size & blood sugar
  - Electrical activity, seizures
- Euphoria
- Abnormal bowel and bladder function

- Toxic effects on muscles including
  - Dystonia, tremors, stereotypy (i.e., ritualistic movements)
- Decreased
  - Brain blood flow & glucose metabolism
  - Appetite & sleep
  - Judgment & complex multi-tasking
- Cardiovascular effects
  - Heart attacks
  - Arrhythmias
  - Severe hypertension
  - Strokes
- Increased potential for violence and psychosis

Stimulant Intoxication: Treat the Presenting Sign/Symptom

Overdose:

Seek immediate medical attention for:

- Hypertensive (HTN) crisis
- Cardiac arrythmias
- Heart attack
- Stroke – Act F.A.S.T.*
- Psychosis

Treatment of Overdose

Treat HTN with alpha and/ or beta blockers

Treat arrythmias with anti-arrhythmics

Treat vasoconstriction with nitroglycerin

BH interventions for Overdose

Talk down the client in a calm environment

Treat agitation with benzodiazepine

Treat psychosis with antipsychotics

* **F**acial drooping, **A**rm weakness, **S**peech difficulty, **T**ime to call 9-1-1

Long-term Mental Effects of Illicit Stimulants

- Tolerance to euphoria and appetite suppression
- **Loss of ability to concentrate & severe memory loss**
- Loss of ability to feel pleasure without drug



- Paranoia and psychosis (hallucinations & delusions)
- Insomnia and fatigue
- Irritability and anger
- **Depression (suicidal ideation)**
- Impulsive, risky sexual behavior

* Use of stimulants in doses approved by FDA for treatment of medical conditions do not result in these effects

Long term Physical Effects of Illicit Stimulants

- **Dry mouth, severe dental decay & gum problems**
- **Bruxism (tooth grinding)**
- Weight loss
- Increased sweating; oily skin
- Skin lesions from injection & formication (leading to skin picking)
- Headaches
- Movement disorders and Seizures
- **Strokes (bleeding into the brain) & heart attacks**
- Irregular heart beats
- Cardiomyopathy
- Kidney & liver failure
- Pulmonary hypertension
- Damaged brain cells
- Neonatal effects



Stimulants and Pregnancy

- Maternal death- pregnancy may increase risk of cardiovascular events
- Preterm labor
- Earlier gestational age at delivery
- Low birth rate
- Small for gestational age
- Strokes in utero
- Secreted in breast milk

Child:
Dysregulated behavior, growth, inhibitory control, attention and abstract reasoning, but these effects appear to be related to gestational age at delivery, psychiatric disorders, other prenatal exposures and quality of postnatal environment. *
Anxiety, depression at 3-year-old **
Worse cognitive function at 7-year-old **

Source: Gouin 2011- cocaine; Kalaitzopoulos, 2018
*Smid, M. C., Metz, T. D., & Gordon, A. J. (2019). Stimulant Use in Pregnancy: An Under-recognized Epidemic Among Pregnant Women. *Clinical obstetrics and gynecology*, *62*(1), 168–184. https://doi.org/10.1097/GRF.0
**Deruf et al. 2007

Stimulant Use in Pregnant People

- Pregnancy
  - During pregnancy stimulant use is more common than opioid use
  - Cannabis is the most used substance during pregnancy
    - Followed by stimulants
- Homelessness and sexual violence predict stimulant use in women…

If Post-traumatic Stress Disorder (PTSD) is present

- Integrated treatment is more effective for co-occurring disorder (COD)

Sources:
- Center for Behavioral Health Statistics Quality. 2015 National survey on drug use and health: Detailed tables In:2016
- Rileya, ED. Risk factors for stimulant use among homeless and unstably housed adult women. Drug Alcohol Depend. 2015 August 1; 153: 173–179. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4510017/pdf/nihms694947.pdf
- Ruglass LM, Hien DA, Hu M, Campbell ANC. Associations Between Post-traumatic Stress Symptoms, Stimulant Use and Treatment Outcomes: A Secondary Analysis of NIDA's Women and Trauma Study. Amer J on Addictions. Vol 23(1): 90-95. Jan-Feb 2014. https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1521-0391.2013.12068.x

Cessation from Stimulants

- Acute withdrawal:
  - 4 days
  - No medication recommended
- Symptoms
  - Increased appetite
  - Increased sleep & dreaming
  - Decreased activity & energy
  - Depression & anhedonia
  - Decreased concentration
  - Craving

- Protracted withdrawal
  - Up to 10 weeks
  - No medication recommended
- Lingering effects on the brain; may be permanent
  - Psychosis
  - Movement Disorders
  - Cognitive Issues

Handout:
Stimulant Withdrawal:
Monitoring & Treatment
https://addictionfreeca.org/r/fpnseg8rpkgg

Amphetamines and Cognitive Impairment

- Two-thirds of people with amphetamine use disorder have cognitive impairment
  - Oxidative Stress
  - Neurotoxicity
  - Neuro Inflammation

- Damage cell structures
  - Mitochondria in neurons & microglia
- Damage DNA
  - Chromosomal alterations
- Inflammation of microglia
- Disruption of blood brain barrier
  - Inflammatory markers in peripheral blood
- Cell death

- Impairment is “associated” with
  - Older age
  - Earlier onset of use
  - Longer duration of use
  - Greater frequency of use

- May limit ability to follow through on treatment

Source: Paulus, M (2020) Neurobiology, clinical presentation, and treatment of methamphetamine use disorder a review. JAMA Psychiatry 77(9): 959-66.

Amphetamines and Lingering Effects on Brain

- May be permanent even with prolonged abstinence
  - Attention
  - Memory
  - Learning efficiency
  - Visual- spatial processing
  - Processing speed
  - Psychomotor speed
  - Executive dysfunction

Cognitive Impairment

Impairs ability to engage in treatment due to trouble

- Sequencing events to get to treatment
- Remembering what is taught
- Applying what is taught

Treatment of Stimulant Use Disorder

- Harm Reduction needed due to IV use & risk of fentanyl
  - Educational materials on psychological & physical effects
  - Fentanyl test strips
  - Syringe Exchange/distribution & other clean injection supplies
  - Naloxone and overdose prevention education
  - Quiet rooms to come down
  - Showers & antibiotics for infection prevention & treatment
  - Condoms & info on safe sex practices
  - Water for hydration
  - Tooth paste and toothbrush



Treatment of Stimulant Use Disorder: SAMHSA Evidence Based Resource Guide

- Motivational Interviewing (MI)
  - Decreased days of stimulant use & amount of stimulant used/ day
- Cognitive Behavior Therapy (CBT)
  - Decreased quantity of stimulant use & frequency/ week
  - Decreased risky sexual behaviors
- Community Reinforcement Approach- see next slide
- Contingency Management- see next slide

STRONG EVIDENCE FOR THESE AS INDIVIDUAL INTERVENTIONS OR IN COMBINATION APPROACHES

Treatment of Stimulant Use Disorder

- Community Reinforcement Approach (CRA)
  - Decreased addiction severity
  - Decreased drug use (weeks of use, frequency/week, $/week)
  - Increased cocaine abstinence
- Contingency Management (CM): Strongest Effect Size
  - Decreased
    - days of stimulant use
    - stimulant cravings
    - HIV risk behaviors
  - Studies Veterans Administration National Rollout
    - Pre-CM: compared to 42% completed 2 sessions in 1 year
    - Post-CM Implementation: 50% completed 14 sessions in 12 week
    - 92% of >69,000 toxicology tests negative

Sources: SAMHSA
Oliva, EM (2013)
Warner & DePhilippis (2020)

How does CM Work?

REMEMBER:
Measure objectively & frequently
Don't set the bar too high or low

- Select objective target behavior (abstinence)
  - Define the behaviors
    - Attendance at clinic (group appt, urine)
    - Abstinence from DOC? all illicit drugs? prescribed drugs? alcohol?
- Provide immediate, consistent, tangible, desired rewards for target behavior
- Escalate size of reward for consistent behavior
- When target behavior does not occur
  - Withhold the reward
  - Reset size of reward for next occurrence of behavior
- Example: Fishbowl Method
  - 250 good job cards/gifts
  - 209 vouchers for $1; 40 for $20; 1 for $100

Reinforcement totaling $80 = treatment as usual. Reinforcements of $240 improves outcomes. Petry 2004

Source: Dominick DePhilippis, Ph.D. Philadelphia CESATE: Center of Excellence in Substance Addiction Tx & Education

In the Chat box please answer this question:

Do you have a Contingency Management Program?

Yes

No

Image provided by Unsplash Photos

References: Stimulant Use

Baicy, K., & London, E. D. (2007). Corticolimbic dysregulation and chronic methamphetamine abuse. Addiction, 102, 5–15. doi:10.1111/j.1360-0443.2006.01777.x

Bolívar HA, Klemperer EM, Coleman SRM, DeSarno M, Skelly JM, Higgins ST. Contingency Management for Patients Receiving Medication for Opioid Use Disorder: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2021 Oct 1;78(10):1092-1102. doi: 10.1001/jamapsychiatry.2021.1969. Erratum in: JAMA Psychiatry. 2022 Jan 26;: PMID: 34347030; PMCID: PMC8340014.

California Department of Public Health. (2020). California Opioid Overdose Surveillance Dashboard. https://skylab.cdph.ca.gov/ODdash/

CDC/NCHS, National Vital Statistics System, Mortality. CDC WONDER, Atlanta, GA: US Department of Health and Human Services, CDC; 2020. https://wonder.cdc.gov/

Chester, N., Mottram, D. R., Reilly, T., & Powell, M. (2004). Elimination of ephedrines in urine following multiple dosing: the consequences for athletes, in relation to doping control. British journal of clinical pharmacology, 57(1), 62–67.

DeFulio A, Rzeszutek MJ, Furgeson J, Ryan S, Rezania S. A smartphone-smartcard platform for contingency management in an inner-city substance use disorder outpatient program. J Subst Abuse Treat. 2021 Jan;120:108188. doi: 10.1016/j.jsat.2020.108188. Epub 2020 Nov 2. PMID: 33298295.

Foulds, J., & Young, J. T. (2019). Pharmacotherapy for incarcerated people with a history of violence: Response to commentary by Schofield et al. Australian & New Zealand Journal of Psychiatry, 54(1), 106–107. doi:10.1177/0004867419885175

Gouin, K., Murphy, K., & Shah, P. S. (2011). Effects of cocaine use during pregnancy on low birthweight and preterm birth: systematic review and metaanalyses. American Journal of Obstetrics and Gynecology, 204(4), 340.e1–340.e12. doi:10.1016/j.ajog.2010.11.013

Hedegaard H, Miniño AM, Warner M. Drug overdose deaths in the United States, 1999–2017. NCHS Data Brief, no 329. Hyattsville, MD: National Center for Health Statistics. 2018.

Hedegaard H, Miniño AM, Warner M. Drug overdose deaths in the United States, 1999–2018. NCHS Data Brief, no 356. Hyattsville, MD: National Center for Health Statistics. 2020.

References: Stimulant Use

Kalaitzopoulos, D.-R., Chatzistergiou, K., Amylidi, A.-L., Kokkinidis, D. G., & Goulis, D. G. (2018). Effect of Methamphetamine Hydrochloride on Pregnancy Outcome. Journal of Addiction Medicine, 12(3), 220–226. doi:10.1097/adm.0000000000000391

Lee, N. K., Jenner, L., Harney, A., & Cameron, J. (2018). Pharmacotherapy for amphetamine dependence: A systematic review. Drug and Alcohol Dependence. doi:10.1016/j.drugalcdep.2018.06.038

Mayo Clinic Laboratories. (2020). Amphetamine-Type Stimulants (ATS). https://www.mayocliniclabs.com/test-info/drug-book/amphetamine.htmll

NCHS, National Vital Statistics System. Estimates for 2019 and 2020 are based on provisional data. Estimates for 2015-2018 are based on final data (available from: https://www.cdc.gov/nchs/nvss/mortality_public_use_data.htm)

NIDA. 2020, April 3. California: Opioid-Involved Deaths and Related Harms. Retrieved from https://www.drugabuse.gov/drug-topics/opioids/opioid-summaries-by-state/california-opioid-involved-deaths-related-harms on 2020, October 7

NIHCM Foundation. (2020). Beyond Opioids: Rapid Increase in Drug Deaths Involving Stimulants. https://www.nihcm.org/categories/beyond-opioids-rapid-increase-in-drug-deaths-involving-stimulants

Oliva, EM, Bowe, T., Harris, A. H., & Trafton, J. A. (2013). Datapoints: False starts in psychotherapy for substance use disorders and PTSD in the VHA. *Psychiatric Services*, *64*(8), 722.

Paulus, M (2020) Neurobiology, clinical presentation, and treatment of methamphetamine use disorder a review. JAMA Psychiatry 77(9): 959-66.

Peirce, JM, et al. (2006). Effects of lower-cost incentives on stimulant abstinence in methadone maintenance treatment: A National Drug Abuse Treatment Clinical Trials Network study. *Archives of General Psychiatry*, *63*(2), 201–208. https://doi.org/10.1001/archpsyc.63.2.201

Petry N., T. J. (2004). Prize reinforcement contingency management for treating cocaine users: how low can we go, and with whom? *Addiction*, 349-360.

References: Stimulant Use

Substance Abuse and Mental Health Services Administration. (2017). Medical Review Officer Guidance Manual for Federal Workplace Drug Testing Programs. https://www.samhsa.gov/sites/default/files/workplace/mro-guidance-manual-oct2017_2.pdf

Substance Abuse and Mental Health Services Administration (SAMHSA). Treatment of Stimulant Use Disorders. SAMHSA Publication No. PEP20-06-01-001 Rockville, MD: National Mental Health and Substance Use Policy Laboratory. Substance Abuse and Mental Health Services Administration, 2020. https://store.samhsa.gov/product/Treatment-of-Stimulant-Use-Disorder/PEP20-06-01-001

Sever, P. S., Dring, L. G., & Williams, R. T. (1975). The metabolism of (?)-ephedrine in man. European Journal of Clinical Pharmacology, 9(2-3), 193–198. doi:10.1007/bf00614017

Smid, M. C., Metz, T. D., & Gordon, A. J. (2019). Stimulant Use in Pregnancy: An Under-recognized Epidemic Among Pregnant Women. Clinical obstetrics and gynecology, 62(1), 168–184. https://doi.org/10.1097/GRF.0000000000000418

U.S. Drug Enforcement Administration, Diversion Control Division. (2019). NFLIS-Drug Special Report: Methamphetamine Reported in NFLIS, 2001–2017. Springfield, VA: U.S. Drug Enforcement Administration. https://www.nflis.deadiversion.usdoj.gov/DesktopModules/ReportDownloads/Reports/12568NFLISdrugMethamphetamine.pdf

Volkow, N. D., & Morales, M. (2015). The Brain on Drugs: From Reward to Addiction. Cell, 162(4), 712–725. doi:10.1016/j.cell.2015.07.046

Werner, D. D. and DePhilippis, D. (2020, August 12). Contingency Management for People Experiencing Homelessness - Homeless and Housing Resource Network SAMHSA Webinar. Washington DC, Washington DC.

Chemsex

Chemsex

Definition:

Chemsex (also known as sexualized drug use – SDU) is the use of drugs to enhance sexual experience. Common drugs used include methamphetamine, gamma-hydroxybutyrate (GHB), gamma-butyrolactone (GBL), cocaine, ketamine, poppers (amyl nitrite) or cannabis (the latter two gave rise to the term SDU)

What You Should Know:

- Chemsex is popular among some gay, bisexual, transgender, and queer persons, **but can be experienced by persons of any gender**
- Chemsex participants have higher odds of condomless anal sex with partners of different or unknown HIV status (bareback sex)
- Persons engaged in Chemsex have greater risk of acquiring sexually transmitted infections (STIs) and hepatitis C (HCV)
- Participants are at higher risk of HIV transmission
- The association with sexual risk indicates the importance of promoting harm reduction among this population (e.g., condoms, PrEP, PEP, drug knowledge).
- Hook-up apps: slang used include PnP, ParTy, Tina, G

SUD and HIV Risk

- The co-occurrence of HIV and SUD in a community increases the risk of HIV transmission due to:
  - Sharing of syringes
  - Intoxicant and/or stimulant involved unprotected sex
  - Sexual violence and victimization
  - Unaware of HIV status
  - Unsuppressed viral load

HIV can be a risk factor for substance use.
But also…
Substance use can be a risk factor for HIV transmission.

Methamphetamine and Its Impact on HIV Infection

Methamphetamine use:

- Decreases sexual inhibitions, impairs judgment, and provides energy and confidence to engage in sexual activity for long periods of time (hyper-sexual)
- Causes erectile dysfunction
- Causes mucosal dryness
- Decreases adherence to HIV treatment and medical follow-up
- Increases HIV replication
- Accelerates progress of HIV-related dementia

Does Methamphetamine Accelerate HIV and HCV?

- In test tube studies, when methamphetamine is added to immune cells, it significantly increases HIV replication
  - Particularly in CD4 cells and monocytes (white blood cells)
- In mouse models, methamphetamine activated a portion of the HIV genetic code (long terminal repeat – LTR), prompting cells to release a protein tied to more rapid HIV disease progression
- The Journal of Viral Hepatitis published a study indicating that methamphetamine increases Hepatitis C replication.

Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2675873/

HIV and Hepatitis C Co-Infections



HIV and Hepatitis C Co-Infections

- In 2018 in Minnesota, there were 60 acute HCV cases and 33,856 chronic cases
  - 8,140 Co-infected for HIV and HCV
- The U.S. Public Health Service/Infectious Diseases Society of America guidelines recommend that all HIV-infected persons be screened for HCV infection (CDC, 2014).

QUESTIONS?

Next Steps

- Join us for **Session 4 next Wednesday!**
- Your registration should have included a reoccurring calendar invite for all four sessions
- **Please complete the evaluation for this session that will be sent out after via email (those requests CEU/CME must complete the evaluations).**

Follow-up questions?

rmaganini@healthmanagement.com

Agenda for Webinar Series

Session	Topics
#1 **WEDNESDAY, MAR 1** 12:00 pm to 3:00 pm	❑ Understanding HIV ❑ HIV Testing and Treatment ❑ The Science of Addiction ❑ Screening, and Assessment
#2 **WEDNESDAY, MAR 8** 12:00 pm to 3:00 pm	❑ Ethical and Legal Issues ❑ Funding and Policy Considerations ❑ HIV Risk Reduction ❑ SUD Harm Reduction ❑ HIV and Stigma ❑ Motivational Interviewing
#3 **WEDNESDAY, MAR 15** 12:00 pm to 3:00 pm	❑ Working with Justice Involved Persons ❑ Substance Use Disorder Treatment with Medications ❑ Mental Health Treatment and Counseling ❑ Stimulant Use ❑ Chem Sex
#4 **WEDNESDAY, MAR 22** 12:00 pm to 3:00 pm	❑ **Cultural, Racial and Sexual Identities** ❑ **HIV Positivity, Pregnancy, and SUD** ❑ **Accessing, Obtaining, and Integrating Services for Individuals with HIV and SUD in Minnesota**